List of Excipients in Branded Drug AURANOFIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Trifluent Pharma LLC	AURANOFIN	auranofin	73352-093	BENZYL ALCOHOL
Trifluent Pharma LLC	AURANOFIN	auranofin	73352-093	CELLULOSE, MICROCRYSTALLINE
Trifluent Pharma LLC	AURANOFIN	auranofin	73352-093	CETYLPYRIDINIUM CHLORIDE

Auranofin Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Auranofin is an FDA-approved oral gold compound supplied as a 3 mg immediate-release capsule under the Ridaura brand. Its original formulation uses conventional capsule excipients, creating opportunities for generic manufacturing, excipient simplification, patient-preference reformulation, and selected 505(b)(2) development programs. The commercial ceiling is limited by a mature rheumatoid arthritis market, historical safety concerns, inexpensive alternative DMARDs, and competition from biologics.

What is the current FDA status of auranofin?

Auranofin received FDA approval in 1985 for the treatment of adults with active rheumatoid arthritis who have not responded adequately to, or cannot tolerate, other antirheumatic therapy. The marketed dose is 3 mg orally twice daily, for a total daily dose of 6 mg.[1]

Attribute	Auranofin status
Active ingredient	Auranofin
Chemical class	Oral gold(I) compound
Approved dosage form	Immediate-release capsule
Approved strength	3 mg
Approved route	Oral
Original brand	Ridaura
Original sponsor	SmithKline Beecham
FDA approval	1985
Primary indication	Rheumatoid arthritis
Current competitive position	Mature, niche, generic-oriented
Biologic risk	Not applicable to the active ingredient; biologic competition affects demand
Patent barrier	No material remaining composition-of-matter or formulation barrier is expected from the original approval era

Ridaura has had periods of limited commercial availability. Current product status should be distinguished from FDA approval status. FDA approval does not guarantee continuous commercial distribution.

What excipients are used in the Ridaura capsule?

The Ridaura label identifies a conventional hard-gelatin capsule formulation containing lactose, microcrystalline cellulose, povidone, crospovidone, magnesium stearate, colloidal silicon dioxide, sodium lauryl sulfate, talc, and capsule-shell materials.[1]

The formulation performs several standard functions:

Excipient or excipient class	Likely function
Lactose monohydrate	Diluent and bulking agent
Microcrystalline cellulose	Filler and compression or capsule-fill aid
Povidone	Binder
Crospovidone	Disintegrant
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow aid
Sodium lauryl sulfate	Wetting or surfactant function
Talc	Processing aid and anti-adherent
Gelatin capsule shell	Dosage-form enclosure

This is a relatively standard oral solid-dose platform. The key formulation issue is not an unusual delivery technology. It is reliable dispersion of a low-dose, potent active in a capsule-fill blend while maintaining content uniformity, dissolution, chemical stability, and acceptable gastrointestinal tolerability.

Auranofin contains a gold atom and a phosphine-thiol-type coordination structure. Its chemical behavior makes control of moisture, excipient impurities, processing conditions, and packaging important. The relevant development question is whether a proposed excipient change alters degradation, dissolution, absorption, or the formation of gold-containing degradation products.

Which excipient changes offer the strongest commercial opportunities?

The strongest near-term opportunity is a lower-complexity generic capsule rather than a novel delivery system.

1. Excipient simplification

A manufacturer could evaluate a reduced excipient platform using:

• Microcrystalline cellulose or lactose as the principal diluent
• Crospovidone or croscarmellose sodium as the disintegrant
• Magnesium stearate as lubricant
• Colloidal silicon dioxide as glidant
• A hard-gelatin or hydroxypropyl methylcellulose capsule shell

The commercial rationale is manufacturing efficiency. Fewer excipients can reduce supplier qualification, blending steps, batch-release testing, and supply-chain exposure. The formulation must still meet blend uniformity and dissolution requirements because the 3 mg strength creates a relatively low-dose content-uniformity challenge.

2. Lactose-free formulation

A lactose-free capsule could target patients with lactose intolerance or buyers seeking a simpler excipient profile. Possible alternatives include:

• Microcrystalline cellulose
• Mannitol
• Dibasic calcium phosphate
• Pregelatinized starch
• Spray-dried starch-based systems

A lactose-free product would have limited ability to command a premium by itself. Its value would be strongest in institutional purchasing, specialty pharmacy differentiation, or a broader excipient-clean-label strategy.

3. Vegetarian capsule shell

Replacing gelatin with hydroxypropyl methylcellulose could address vegetarian, religious, and selected institutional procurement requirements. This is a practical line-extension opportunity because the active remains in the same immediate-release oral dosage form.

The primary development risks are shell moisture behavior, fill compatibility, stability, and dissolution. A shell change can be commercially useful without creating a new therapeutic product, but it may require regulatory support beyond a simple manufacturing change depending on the regulatory pathway and the reference product.

4. Surfactant reduction or removal

Sodium lauryl sulfate may improve wetting and dispersion, but it can contribute to gastrointestinal irritation in susceptible patients. A formulation that achieves equivalent dissolution without sodium lauryl sulfate could support a tolerability-oriented product position.

Potential substitutes include polysorbates, sodium dioctyl sulfosuccinate, or no surfactant if particle-size and wetting studies support removal. Each substitute creates new impurity, oxidation, compatibility, and regulatory considerations. Removing sodium lauryl sulfate is commercially attractive only if the change preserves bioequivalence and materially improves the excipient profile.

5. Modified-release or enteric systems

A modified-release product could theoretically reduce peak-related exposure or gastrointestinal intolerance. It is a higher-risk opportunity because the approved product is immediate release and auranofin’s clinical use depends on an established systemic exposure profile.

A modified-release program would likely require:

• New in vitro release specifications
• Pharmacokinetic bridging
• Dose-exposure analysis
• Potential clinical efficacy and safety support
• A 505(b)(2) application rather than a conventional ANDA

The development cost and regulatory risk are disproportionate to the likely size of the rheumatoid arthritis market unless the formulation supports a new indication or materially improves safety.

How should auranofin excipients be selected?

Auranofin formulation development should prioritize chemical compatibility and dose uniformity over novelty.

Excipient selection priorities

Development issue	Preferred strategy
Low dose	Use a high-uniformity premix and validated geometric dilution process
Moisture sensitivity	Evaluate low-moisture excipients and high-barrier packaging
Flowability	Use controlled-particle-size diluent and limited glidant
Dissolution	Confirm that lubricant level and hydrophobic excipients do not delay release
Chemical stability	Conduct compatibility studies under heat, humidity, and light
Capsule integrity	Compare gelatin and HPMC shells under long-term storage
Patient acceptability	Consider lactose-free and surfactant-reduced alternatives
Manufacturing scale-up	Select excipients with robust supplier continuity and compendial support

The main technical risk is over-lubrication. Excess magnesium stearate can reduce wettability and slow dissolution. The risk is more relevant where the active is poorly dispersed or where surfactant is removed from the formula.

Moisture control also matters. Auranofin should be evaluated with the final container-closure system, not only in open-dish excipient compatibility studies. Blister packaging, high-density polyethylene bottles with desiccant, and moisture-barrier induction seals are potential options.

What generic and regulatory pathways apply to auranofin?

A product that matches the reference product in active ingredient, strength, dosage form, route, and labeled conditions of use may be eligible for an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act.[2]

A formulation with a meaningful change in release profile, dosage form, indication, or clinical use would more likely require a 505(b)(2) application. The pathway depends on the extent of reliance on FDA’s prior findings for auranofin and the amount of new clinical evidence required.

ANDA-oriented strategy

An ANDA formulation should focus on:

• Same 3 mg strength
• Immediate-release capsule
• Equivalent qualitative and quantitative composition where practical
• Comparative dissolution
• Bioequivalence
• Stability and impurity control
• Adequate controls for blend uniformity

Excipient substitutions are possible, but they increase the need for comparative dissolution and bioequivalence justification. A simple qualitative or quantitative change does not automatically create a new patent position.

505(b)(2)-oriented strategy

A 505(b)(2) program could support:

• A new modified-release profile
• A new dosage form
• A new route of administration
• A new indication
• A clinically differentiated tolerability profile
• A formulation designed for patients unable to swallow conventional capsules

The commercial case would need to exceed generic price competition. A new formulation without a clear clinical advantage would face a weak return profile.

What patents protect auranofin and its formulations?

Auranofin was approved in the mid-1980s, and the original composition-of-matter, formulation, and approval-era exclusivities would have expired long ago. The practical IP environment is therefore different from that for a recently approved small molecule.

IP category	Practical assessment
Original active-ingredient patents	Expected to be expired
Original Ridaura formulation patents	Expected to be expired
FDA exclusivity from 1985 approval	Expired
Current Orange Book blocking patent	No material current barrier is expected
New excipient formulation patents	Potentially available if technically non-obvious
New indication patents	Potentially available, subject to patentability and clinical support
Manufacturing-process patents	Possible, but generally narrower and easier to design around
Trade-secret value	Blend order, process parameters, analytical methods, and packaging controls

A new patent should not rely solely on replacing lactose with mannitol or gelatin with HPMC. Those changes may be difficult to defend unless linked to a specific technical effect, such as improved chemical stability, reduced degradation, improved dissolution, or demonstrated patient benefit.

More defensible claims could cover:

• A defined particle-size distribution
• A specific excipient ratio that improves content uniformity
• A moisture-controlled composition
• A stability-enhancing packaging system
• A novel release profile
• A formulation that reduces a clinically relevant adverse effect
• A new therapeutic use supported by credible clinical data

Are there Paragraph IV challenges involving auranofin?

Auranofin is a mature product, so any modern ANDA applicant could potentially file a Paragraph IV certification against an unexpired patent listed in the Orange Book. However, the original Ridaura patent estate does not create the type of active litigation risk associated with newer branded drugs.

The key legal distinction is between:

1. A generic auranofin capsule relying on the FDA reference product; and
2. A new formulation or indication relying on a 505(b)(2) pathway.

A conventional generic would face ordinary ANDA patent certification requirements. A new excipient strategy would not automatically create patent protection or regulatory exclusivity. A formulation patent would need to be listed and enforceable, and a Paragraph IV filing could trigger Hatch-Waxman litigation under 35 U.S.C. §271(e)(2).

No material current auranofin patent litigation or settlement framework is associated with the original product in the public domain used for this assessment.

What formulation patents could create commercial exclusivity?

The most credible formulation patent themes are narrow technical claims rather than broad excipient substitutions.

Potentially valuable claim categories

A patent portfolio could target:

• Auranofin with a specified moisture content
• Auranofin combined with a defined surfactant-free excipient system
• Auranofin in a gastroprotective or delayed-release dosage form
• Auranofin with a specific particle-size distribution
• A capsule composition with improved content uniformity at 3 mg
• A stable HPMC capsule formulation
• Auranofin with a defined degradation-product profile
• Auranofin for a new inflammatory, infectious, or oncology indication

Commercial strength would depend on whether the claims cover the product that competitors must sell. A broad, easily substituted excipient claim would have limited enforcement value. A claim tied to a measurable performance advantage would be stronger.

What biosimilar risk exists for auranofin?

There is no biosimilar risk because auranofin is a chemically synthesized small molecule, not a biologic. The relevant competitors are:

• Generic auranofin capsules
• Conventional synthetic DMARDs
• Biologic DMARDs used in rheumatoid arthritis
• Targeted synthetic DMARDs
• Off-label or investigational auranofin products

Biologic competition still affects auranofin’s commercial opportunity because modern rheumatoid arthritis treatment often uses methotrexate, TNF inhibitors, interleukin inhibitors, abatacept, rituximab, or JAK inhibitors. Auranofin is therefore more likely to compete as a low-cost niche therapy than as a first-line rheumatoid arthritis product.

Which commercial opportunities are most attractive?

Opportunity	Commercial attractiveness	Main barrier
Low-cost generic 3 mg capsule	Moderate	Limited market size and price erosion
Lactose-free capsule	Low to moderate	Weak willingness to pay
Vegetarian HPMC capsule	Low to moderate	Limited differentiation
Simplified manufacturing formula	Moderate	Requires bioequivalence and stable supply
Modified-release capsule	Low to moderate	High development and regulatory cost
New indication	Potentially high	Clinical and patent risk
Specialty formulation for tolerability	Moderate	Need clinically meaningful evidence
Combination product	Low initially	Complex regulatory and clinical program
Contract manufacturing	Moderate	Competitive CMO market
Repurposed investigational product	Potentially high	Uncertain efficacy and funding requirements

The best risk-adjusted opportunity is a reliable generic or specialty generic product with a differentiated excipient profile, supported by low manufacturing cost and dependable supply. A high-value opportunity would require a new indication or clinically demonstrated tolerability benefit.

How does auranofin compare with competing rheumatoid arthritis therapies?

Auranofin has a lower development and manufacturing burden than biologics but a weaker clinical and commercial position.

Product class	Formulation complexity	Development cost	Market position
Auranofin capsules	Low	Low for generic; high for new indication	Niche
Methotrexate tablets	Low	Low	Established conventional DMARD
Hydroxychloroquine tablets	Low	Low	Established conventional DMARD
Biologic DMARDs	High	High	Major specialty market
JAK inhibitors	Moderate to high	High	Differentiated oral specialty market

Auranofin’s value proposition is oral administration and an established regulatory history. Its disadvantages include adverse-effect monitoring, slower clinical uptake than modern targeted therapies, and limited ability to command premium pricing.

What manufacturing and supply-chain barriers affect auranofin?

Auranofin requires specialized handling compared with ordinary non-metal-containing capsule products. Potential barriers include:

• Reliable supply of pharmaceutical-grade auranofin
• Gold-content assay and elemental impurity control
• Reproducible low-dose blending
• Control of degradation products
• Compatibility with excipients and capsule shells
• Packaging that limits moisture and light exposure
• Validated analytical methods for assay, impurities, dissolution, and content uniformity

The active pharmaceutical ingredient supply base is likely narrower than for high-volume generic drugs. That factor can support contract manufacturing or regional supply opportunities, but it also raises minimum-scale and procurement risks.

A manufacturer should also assess elemental impurity requirements under ICH Q3D and product-specific analytical controls. The presence of gold does not eliminate the need to characterize other elemental impurities arising from raw materials, equipment, and processing.[3]

What is the likely generic launch scenario?

A generic entrant would most likely launch as a 3 mg immediate-release capsule with a familiar excipient system and limited promotional investment. Pricing pressure would be substantial if multiple suppliers enter. A single-source or limited-source market could support better margins, particularly if the supplier offers:

• Reliable year-round availability
• A lactose-free or vegetarian capsule
• Institutional packaging
• Multiple bottle counts
• Stable supply to specialty pharmacies
• Strong documentation for procurement and formulary review

A novel formulation would have a better launch profile only if it obtains meaningful differentiation, such as a new indication, reduced gastrointestinal toxicity, improved adherence, or a meaningful patent term.

Key Takeaways

• Auranofin is an FDA-approved 3 mg immediate-release oral capsule for rheumatoid arthritis.
• Its original excipient system is conventional and does not create a strong modern product moat.
• The most practical near-term opportunity is a low-cost generic or specialty generic capsule.
• Lactose-free, surfactant-reduced, and HPMC-shell products offer commercial differentiation but limited standalone pricing power.
• Modified-release and other advanced formulations would likely require a 505(b)(2) strategy and substantial clinical justification.
• The original auranofin patent and exclusivity position is effectively exhausted.
• New patents could focus on demonstrated stability, dissolution, content uniformity, tolerability, manufacturing, or new therapeutic uses.
• Auranofin has no biosimilar risk, but it faces competition from generic DMARDs, biologics, and targeted synthetic therapies.
• The strongest long-term commercial opportunity would depend on a new indication or clinically validated formulation advantage.

FAQs

Can auranofin be reformulated as a tablet?

Yes, but a tablet would be a dosage-form change from the approved capsule and could require a 505(b)(2) pathway or other regulatory support. A conventional generic strategy should remain aligned with the reference capsule unless the tablet provides a documented clinical or manufacturing advantage.

Is auranofin suitable for a lactose-free product?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, starch, or another compatible diluent. The replacement must preserve content uniformity, dissolution, stability, and bioequivalence.

Could an HPMC capsule create new auranofin patent protection?

Potentially, but the patent would need more than the use of a vegetarian shell. Stronger protection would require a non-obvious formulation relationship, such as improved stability, a specific moisture profile, or a measurable dissolution or tolerability benefit.

Does auranofin require biologic interchangeability analysis?

No. Auranofin is a small-molecule drug. Generic approval is governed by the ANDA framework rather than the biosimilar and interchangeable-biologic framework.

Is auranofin a strong candidate for repurposing?

It may be considered for repurposing because it has an established oral safety and manufacturing history, but a commercial repurposing program would require credible clinical evidence in the new indication. The value would depend on the target disease, clinical differentiation, and ability to obtain enforceable method-of-use or formulation protection.

References

1. DailyMed. (n.d.). Ridaura- auranofin capsule prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA): Generics. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

3. International Council for Harmonisation. (2014). ICH Q3D(R2): Guideline for elemental impurities. https://www.ich.org

4. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

5. U.S. Food and Drug Administration. (n.d.). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/types-applications/505b2-applicationjul2019